Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Mineralys Stock

Q: Can you buy Mineralys stock?

You can no longer buy Mineralysstock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

mineralystx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $159.18MM

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone levels. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension. The company has plans for the continued research and development of lorundrostat in hypertension and other potential indications. Mineralys Therapeutics was founded in 2019, and is headquartered in Radnor, Pennsylvania.

Learn more about Mineralys IPO

Enterprise Value

Access valuation and stock price for companies like Mineralys before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Mineralys stock FAQs

Can you buy Mineralys stock?

You can no longer buy Mineralys stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

How to buy Mineralys stock?

To invest in a private company like Mineralys through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Mineralys stock?

You can no longer sell stock of Mineralys on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

How to sell Mineralys stock?

If you hold private company shares of Mineralys - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Mineralys stock on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

Is Mineralys a public company?

No, Mineralys is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Mineralys’ stock price?

The stock price of Mineralys is $8.27 as of 1/18/24.

What is Mineralys’ stock ticker symbol?

The ticker symbol of Mineralys is MLYS.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Mineralys investors also invested in these private companies

Adams Street Partners

Glean, Arctic Wolf, BillionToOne, VillageMD, Couchbase, Abra, FalconX, GoCardless, Homeward, Axonius

Ra Capital Management

X-energy, Element Biosciences, Mindtickle, BioAge, Freenome, Capstan Therapeutics, Synthego, Sionna Therapeutics, FogPharma, Bicara Therapeutics

Rock Springs Capital

Freenome, Zenas BioPharma, Caris Life Sciences, Delfi Diagnostics, Kindbody, FogPharma, Vedanta Biosciences, Hemab Therapeutics, Mineralys

Samsara Biocapital

Attralus, Alumis, Delfi Diagnostics, FogPharma, Spyglass Ophthalmics, Obsidian Therapeutics, RayzeBio, Alamar Biosciences, Acelyrin, Mineralys

RTW Investments

Beta Bionics, BioAge, Santa Ana Bio, Obsidian Therapeutics, Lycia Therapeutics, Acelyrin, Apogee Therapeutics, Mineralys

Andera Partners

Evommune, Mineralys

Team

Management Team

Jon Congleton

Chief Executive Officer

David Rodman, MD

Chief Medical Officer

Adam Levy

Chief Financial Officer & Chief Business Officer

Board Members

Olivier Litzka, PhD

Andera Partners

Derek DiRocco, PhD

RA Capital Management

Takeshi Takahashi

Catalys Pacific

Philadelphia Business Journal 02/14/2023

Mineralys Therapeutics sets IPO target at up to $160M

The Main Line biopharmaceutical company stated in documents filed with the SEC that it plans to sell 10 million shares of common stock.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.